A Phase II, Open Label, Single Arm Trial to Evaluate the Pharmacokinetics,Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Antiretroviral Naive HIV-1 Infected Adolescents and Children Aged > = 6 to <18 Years

Trial Profile

A Phase II, Open Label, Single Arm Trial to Evaluate the Pharmacokinetics,Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Antiretroviral Naive HIV-1 Infected Adolescents and Children Aged > = 6 to <18 Years

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Rilpivirine (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacokinetics
  • Acronyms PAINT
  • Sponsors Janssen R&D Ireland
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 21 Mar 2017 Planned primary completion date changed from 1 Jan 2020 to 10 Jan 2020.
    • 23 Dec 2016 Planned number of patients changed from 56 to 61.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top